Pros
It has a peptide drug for anemia that is likely to be approved by the FDA. The drug has efficacy, low cost of goods, and is a good candidate for Medicare preference for the treatment of anemia for the dialysis patient population. The safety profile and monthly administration of the drug is a big advantage over the currently marketed drugs for anemia.
Cons
No more research for new targets for new drugs in the pipeline. All work was focused on the one drug; what is next? Unless a new target is identified, there isn't much for people at Affymax to do. They already laid off 95% of the researchers, so all that history and expertise is gone. It seems to be solely focused on getting Hematide through the trials, and now that they are ready to submit data to the FDA, what happens to anyone who isn't in sales and marketing?